SITRICK MICHAEL S 4
4 · Abraxis BioScience, Inc. · Filed Oct 19, 2010
Insider Transaction Report
Form 4
SITRICK MICHAEL S
Director
Transactions
- Disposition to Issuer
Non-qualified Stock Option
2010-10-15$35.06/sh−10,000$350,600→ 0 totalExercise: $38.08From: 2010-12-10Exp: 2019-12-10→ Common Stock (10,000 underlying)
Footnotes (1)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of June 30, 2010, among Celgene Corporation ("Celgene"), Artistry Acquisition Corp. ("Merger Sub") and Abraxis BioScience, Inc. ("Abraxis"), whereby Merger Sub merged into Abraxis, with Abraxis continuing as the surviving company and a wholly owned subsidiary of Celgene (the "Merger"), this option, which was granted, and became exercisable, on December 10, 2009, was cancelled in exchange for (i) a cash payment of $350,600.00, which represents the excess of $73.14 per share over the exercise price per share of this option and (ii) a contingent value right issued by Celgene.